We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00899769
First Posted: May 12, 2009
Last Update Posted: March 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Vanderbilt University Medical Center
May 9, 2009
May 12, 2009
March 14, 2017
April 2005
Not Provided
  • Differences in serum protein profiles and differences in the number of peptide matches
  • Protein levels and the largest difference in peptide matches in sera
Same as current
Complete list of historical versions of study NCT00899769 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers
Serum Biomarkers for Head and Neck Cancer

RATIONALE: Studying samples of blood, tissue, and saliva in the laboratory from patients with cancer and from healthy volunteers may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This laboratory study is looking at biomarkers in patients with head and neck cancer and in healthy volunteers.

OBJECTIVES:

  • Correlate the differences in serum protein profiles with the differences in the number of peptide matches in patients with squamous cell carcinoma of the head and neck and in healthy volunteers.
  • Correlate protein levels with the largest difference in peptide matches in sera in these participants.

OUTLINE: This is a prospective study.

Participants undergo blood, tissue, and saliva collection for biological studies. Samples are analyzed for albumin-bound and non-albumin-bound proteins or IgG via liquid chromatography and tandem mass spectrometry (LC-MS-MS), ELISA, proteomic profiling, and protein expression.

PROJECTED ACCRUAL: A total of 50 patients and 50 healthy volunteers will be accrued for this study.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Head and Neck Cancer
  • Genetic: protein expression analysis
  • Genetic: proteomic profiling
  • Other: immunoenzyme technique
  • Other: laboratory biomarker analysis
  • Other: liquid chromatography
  • Other: mass spectrometry
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Meets one of the following criteria:

    • Diagnosis of squamous cell carcinoma of the head and neck
    • Healthy volunteer matched by sex, race, birth decade, or smoking status (e.g., current smoker, former smoker, or nonsmoker)

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00899769
CDR0000546781
P30CA068485 ( U.S. NIH Grant/Contract )
VU-VICC-HN-0530
VU-VICC-IRB-050230
Not Provided
Not Provided
Not Provided
Vanderbilt University Medical Center
Vanderbilt University Medical Center
National Cancer Institute (NCI)
Study Chair: Wendell G. Yarbrough, MD, FACS Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
March 2017